ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer

Metastatic Prostate Carcinoma Clinical Trial

Official title:

Phase II Multi-Center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic Castrate Resistant Prostate Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04159896
• Other study ID #: 2019-031
• Secondary ID: P30CA022453
• Status: Recruiting
• Phase: Phase 2
• Start date: November 13, 2019
• Est. completion date: March 1, 2022

Study information

• Verified date: October 2020
• Source: Barbara Ann Karmanos Cancer Institute
• Contact: Elisabeth Heath, M.D.
• Phone: 313-576-8717
• Email: heathe[@]karmanos.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase II trial studies the side effects of ESK981 and nivolumab and to see how well they work for the treatment of castration resistant prostate cancer that has spread to other places in the body (metastatic). ESK981 is an investigational drug that targets several important pathways that are believed to play a role in the spread of cancer. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This study is being done to see if giving ESK981 and nivolumab together works better in treating metastatic castration resistant prostate cancer compared to usual treatments.

Description:

PRIMARY OBJECTIVES:

I. To determine the prostate specific antigen (PSA) >= 50% response rate (PSA50) from baseline using the Prostate Cancer Clinical Trials Working Group 3 (PCWG3) criteria to pan-VEGFR/TIE2 tyrosine kinase inhibitor CEP-11981 (ESK981) plus nivolumab in men with metastatic castration resistant prostate cancer (mCRPC) who have progressed on enzalutamide (an oral androgen-receptor inhibitor) and/or abiraterone acetate (an androgen synthesis inhibitor) and chemotherapy (docetaxel and/or cabazitaxel).

II. To assess the safety and tolerability of ESK981 plus nivolumab.

SECONDARY OBJECTIVES:

I. To determine the time to PSA response (TTPR) in patients with mCRPC. II. To determine the duration of PSA response (PRD) in patients with mCRPC. III. To determine PSA progression rates as defined by the PCWG3 criteria. IV. To determine PSA progression free survival (PPFS) as defined by the PCWG3 criteria.

CORRELATIVE/EXPLORATORY/TERTIARY OBJECTIVE:

I. To assess exploratory biomarkers from blood and tumor biopsies.

OUTLINE:

Patients receive ESK981 orally (PO) once daily (QD) for 5 consecutive days per week, followed by a 2-day break. Patients also receive nivolumab intravenously (IV) on day 1 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 3 months for 5 years.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 49
• Est. completion date: March 1, 2022
• Est. primary completion date: March 1, 2022
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Eastern Cooperative Group (ECOG) performance status =< 1

• Recovery to baseline or =< grade 1 Common Terminology Criteria for Adverse Events (CTCAE) version (v.)5 from toxicities related to any prior treatments, unless adverse event (AE)(s) are clinically non-significant and/or stable on supportive therapy

• Absolute neutrophil count (ANC) >= 1.5 K/mm^3

• Hemoglobin (Hgb) >= 9 g/dL

• Platelets (Plt) >= 100,000/mm^3

• Serum creatinine =< 1.5 times the upper limit of normal OR creatinine clearance > 30 mL/min by Cockcroft-Gault formula

• Total bilirubin =< 1.5 x upper limit of normal (ULN)

• Aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN with known hepatic metastases)

• Alanine aminotransferase (ALT) =< 2.5 x ULN (=< 5 x ULN with known hepatic metastases)

• Prothrombin time (PT) and activated partial thromboplastin time (aPTT) levels =< 1.5 x ULN (If patient is receiving anticoagulation that is expected to alter these levels, should be in targeted therapeutic range for that agent)

• Patient must have progressive disease while receiving androgen deprivation therapy (ADT) defined by any one of the following as per the PCWG3 criteria for PSA, measurable or non-measurable (bone) disease and must have a castrate serum testosterone level (i.e. =< 50 ng/dL) at screening:

• PSA: At least two consecutive rises in serum PSA, obtained at a minimum of 1-week intervals, with the final value >= 2.0 ng/mL

• Measurable disease (by Response Evaluation Criteria in Solid Tumors [RECIST] 1.1): >= 20% increase (with an absolute increase of at least 5 mm) in the sum of diameters of all measurable lesions or the development of one or more new lesions. The short axis of a target lymph node must be more than 15 mm to be assessed for change in size

• Non-measurable (bone) disease: The appearance of two or more new areas of uptake on bone scan consistent with metastatic disease compared to previous imaging during castration therapy. The increased uptake of pre-existing lesions on bone scan will not be taken to constitute progression, and ambiguous results must be confirmed by other imaging modalities (e.g. X-ray, computed tomography [CT] or magnetic resonance imaging [MRI])

• Metastatic prostate cancer (M1) as documented by appropriate medical imaging (i.e. CT-Scan, positron emission tomography [PET] scan or bone scan)

• Progression on a hormonal agent (abiraterone/enzalutamide) and on a chemotherapy agent (docetaxel and/or cabazitaxel) in the metastatic castration resistant setting as per PCWG3 criteria

• Progression on chemotherapy (e.g. docetaxel, cabazitaxel) in the metastatic castration resistant setting. Progression of disease within 6 months of completing docetaxel in the metastatic castrate-sensitive setting is acceptable

• Have signed an informed consent document indicating that the subject understands the purpose of and procedures required for the study and are willing to participate in the study

• Be willing and able to adhere to the prohibitions and restrictions specified in this protocol

• Willingness to use contraception by a method that is deemed effective by the investigator throughout the treatment period and for at least 30 days following the last dose of therapy

• Willingness and ability to comply with study procedures and follow-up examination

• Able to swallow and retain oral medication

• Willingness and ability to undergo mandatory tumor biopsy at baseline and at the cycle 3 visit

• Willingness and ability to undergo mandatory whole blood sample collections at baseline, weeks 2-4 in the first cycle, and then monthly

Exclusion Criteria:

• Systemic therapy (other than a gonadotrophin releasing hormone [GnRH] agonist/antagonist) for CRPC within the past two weeks from cycle 1/day 1 including:

• CYP-17 inhibitors (e.g. ketoconazole, abiraterone)

• Antiandrogens (e.g. bicalutamide, nilutamide)

• Second generation antiandrogens (e.g. enzalutamide, ARN-509, galeterone)

• Immunotherapy (e.g. sipuleucel-T, ipilimumab)

• Chemotherapy (e.g. docetaxel, cabazitaxel)

• Prior radiopharmaceutical therapy (e.g. radium-223, strontium-89, samarium-153, etc.) within the past year

• Have any condition that, in the opinion of the investigator, would compromise the well-being of the subject or the study or prevent the subject from meeting or performing study requirements

• The patient is currently on warfarin or heparin therapy

• The patient has any pre-existing coagulopathy, recent hemoptysis, gross hematuria or gastrointestinal bleeding

• The patient has a history of a clinically significant cardiovascular or cerebrovascular event within 3 months prior to study entry

• The patient has uncontrolled hypertension defined as a blood pressure measurement greater than 150 mm Hg systolic or 90 mm Hg diastolic with medication

• The patient has previously been enrolled in the study or received ESK981

• The patient has known hypersensitivity to gelatin or lactose monohydrate

• The patient has taken a medication known to be a potent inducer of CYP1A2, CYP2C8, or CYP3A4 within 4 weeks prior to the first dose of study drug

• Prior treatment with anti-PD/PD-L1/CTLA4/IDO antibody

• Untreated brain metastases or spinal cord compression

• Major surgical procedure or significant traumatic injury within 6 weeks prior to study registration. (> 6 weeks prior to registration is permitted as long as they have fully recovered from any such procedure)

• History of another primary malignancy except for: malignancy treated with curative intent and no known active disease for >= 5 years, adequately treated non-melanoma skin cancer without evidence of disease, adequately treated carcinoma in situ without evidence of disease

• Angina, myocardial infarction symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack, arterial embolism, pulmonary embolism, percutaneous angioplasty or Coronary arterial bypass surgery within the past 3 months

• The patient has received any investigational drug within 28 days prior to registration or 5 half-lives of the investigational drug, whichever is sooner

Related Conditions & MeSH terms

• Carcinoma
• Castration Levels of Testosterone
• Castration-Resistant Prostate Carcinoma
• Metastatic Prostate Carcinoma
• Prostate Carcinoma Metastatic in the Bone
• Prostatic Neoplasms
• Stage IVB Prostate Cancer AJCC v8

Intervention

Drug:
• Pan-VEGFR/TIE2 Tyrosine Kinase Inhibitor CEP-11981
Given PO

Biological:
• Nivolumab
Given IV

Locations

Country	Name	City	State
United States	University of Michigan Comprehensive Cancer Center	Ann Arbor	Michigan
United States	Wayne State University/Karmanos Cancer Institute	Detroit	Michigan

Sponsors (2)

Lead Sponsor	Collaborator
Barbara Ann Karmanos Cancer Institute	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Somatic and germline mutations	Will assess the proportion of patients with TP53 mutations, AR amplifications, and ETS-fusions, mutations in the PTENPI3K-AKT pathway as well as germline and somatic events in the DNA repair pathway with exceptional response/resistance to pan-VEGFR/TIE2 tyrosine kinase inhibitor CEP-11981 (ESK981).	Up to 5 years
Other	ETS/kinase gene fusions	Will assess the proportion of patients with ETS/kinase gene fusions with exceptional response/resistance to ESK981.	Up to 5 years
Other	Androgen receptor (AR) signaling	Will assess the correlation of AR signaling as a predictor of exceptional response to ESK981.	Up to 5 years
Other	Metastatic kinome activity profiles as predictive biomarkers for response to ESK981	Will assess the correlation of Metastatic kinome activity profiles as a predictor for exceptional response to ESK981	Up to 5 years
Other	Circulating and disseminated tumor cells as pharmacodynamic biomarkers of ESK981 response	Will assess the correlation of circulating and disseminated tumor cells as a predictor for exceptional response to ESK981 .	Up to 5 years
Other	Pathological assessment of phenotypic tumor and host responses to ESK981 treatment	Will assess the correlation of IHC % staining as a predictor for exceptional response to ESK981 .	Up to 5 years
Primary	Prostate specific antigen (PSA) >= 50% response rate (PSA50)	Will assess PSA decline of >= 50% from baseline (PSA50), using the Prostate Cancer Working Group 3 (PCWG3) criteria. 1-sided Wilson type 90% lower confidence interval (CI) estimates will be calculated.	Up to 5 years
Primary	Incidence of adverse events	Adverse events of all grades will be captured by the National Cancer Institute - Common Terminology Criteria for Adverse Events, version 5 (NCI-CTCAE v5) and Good Clinical Practice (GCP) standards. Other statistics will include point and (2-sided) CI estimates of overall toxicity and of specific types of toxicity.	Up to 30 days after last dose
Secondary	Time to PSA response (TTPR)	Descriptive statistics of TTPR will be used to summarize the time to PSA response. These descriptives will include N, median, mean, standard deviation (SD), interquartile range (IQR), minimum, and maximum.	From treatment start until the first documented occurrence of PSA50, assessed up to 5 years
Secondary	Duration of PSA response (PRD)	The censored distributions will be summarized with the Kaplan-Meier (K-M) survivorship estimate. A graph of the K-M curve will be generated along with the Hall-Wellner 90% confidence band, and a display of the number of patients at risk at several time points, below the X-axis. Summary statistics (6-month rate, 12-month rate, median, etc.) will be calculated from the K-M life table, each one with its respective 80% CI.	From start of PSA50 until PSA progression, assessed up to 5 years
Secondary	PSA progression free survival (PPFS)	PSA progression rates will be estimated from the PSA-only PFS distribution. PSA progression is defined as the date that a 25% or greater increase and an absolute increase of 2.0 ng/mL or more from the nadir is documented and confirmed by a second value obtained 3 or more weeks later. Where no decline from baseline is documented, PSA progression is defined as a 25% increase from the baseline value along with an increase in absolute value of 2.0 ng/mL or more after 8 weeks. The censored distributions will be summarized with the K-M survivorship estimate. A graph of the K-M curve will be generated along with the Hall-Wellner 90% confidence band, and a display of the number of patients at risk at several time points, below the X-axis. Summary statistics (6-month rate, 12-month rate, median, etc.) will be calculated from the K-M life table, each one with its respective 80% CI.	Up to 5 years